Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 148,100 shares at $143.61 ($21.2M) on 2023-04-19, disclosed to the SEC on 2023-04-21.
Scheduled sale ($21.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $141.94 | 11,900 | $1.7M | 8.0% |
| 2 | $142.95 | 14,038 | $2.0M | 9.5% |
| 3 | $142.95 | 14,038 | $2.0M | 9.5% |
| 4 | $143.61 | 14,062 | $2.0M | 9.5% |
| 5 | $143.61 | 14,062 | $2.0M | 9.5% |
| 6 | $141.35 | 6,752 |
| $954K |
| 4.5% |
| 7 | $141.35 | 6,752 | $954K | 4.5% |
| 8 | $142.24 | 8,780 | $1.2M | 5.9% |
| 9 | $142.24 | 8,780 | $1.2M | 5.9% |
| 10 | $143.53 | 16,495 | $2.4M | 11.2% |
| 11 | $143.53 | 16,495 | $2.4M | 11.2% |
| 12 | $144.08 | 7,973 | $1.1M | 5.4% |
| 13 | $144.08 | 7,973 | $1.1M | 5.4% |
| Total | $143.01 avg | 148,100 | $21.2M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |